Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 140

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 140
---
 Herein Exhibit Number Description Form Date 77

10.20 Common Stock Purchase Agreement between the Company and Amgen Inc., dated September 28, 2016 Amendment No. 1 to the Registration Statement on Form S-3, as Exhibit 10.1) November 25, 2016 10.21† License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018† Quarterly Report on Form 10-Q, as Exhibit 10.1 February 7, 2019 10.22† Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018† Annual Report on Form 10-K, as Exhibit 10.19 November 25, 2019 10.23† Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February 4, 2019† Annual Report on Form 10-K, as Exhibit 10.20 November 25, 2019 10.24† Amended and Restated License Agreement by and between Arrowhead Pharmaceuticals, Inc. and GlaxoSmithKline Intellectual Property (No. 3) Limited, dated December 11, 2023 Quarterly Report on Form 10-Q, as Exhibit 10.1 August 8, 2024 10.25 Stock Purchase Agreement by and between Johnson & Johnson Innovation-JJDC, Inc. and Arrowhead Pharmaceuticals, Inc., dated October 3, 2018 Quarterly Report on Form 10-Q, as Exhibit 10.3 February 7, 2019 10.26† Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc., dated October 7, 2020† Quarterly Report on Form 10-Q, as Exhibit 10.1 February 4, 2021 10.27 First Amendment to Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. dated March 15, 2022 Quarterly Report on Form 10-Q, as Exhibit 10.1 May 10, 2022 10.28† Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics Ireland DAC, dated June